ArticleAnnals of surgical oncology2026
Axillary Management in Breast Cancer Patients with Positive Lymph Nodes Following Neoadjuvant Chemotherapy.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently, patients with biopsy-proven axillary disease undergoing neoadjuvant chemotherapy (NAC) must undergo completion axillary lymph node dissection (cALND) if there is residual disease in the sentinel lymph nodes (SLN). In the era of axillary de-escalation, our objectives were to evaluate the frequency of involved non-SLN during cALND and whether clinical, radiologic, and pathologic characteristics can predict non-SLN involvement.
methodsThis was a multicenter, retrospective cohort study of patients with biopsy proven node-positive breast cancer between 2012 and 2024, who had residual nodal metastases (ypN+) post NAC and underwent cALND following SLN biopsy (SLNB) or targeted axillary lymph node dissection (TAD). Patients were grouped by the presence or absence of positive non-SLN at cALND (cALND+ vs. cALND-). Descriptive statistics were used to compare demographic, radiologic and pathologic data between groups. Univariate and multivariate analyses were used to identify predictors of cALND+.
resultsOverall, 122 ypN+ patients were included in the study; 57 (46.7%) had cALND+. Predictors of cALND+ on multivariate analysis included the number of abnormal lymph nodes on pretreatment axillary ultrasound (odds ratio [OR] 3.74, 95% confidence interval [CI] 1.5-10, p = 0.006), SLN extracapsular extension on final pathology (OR 2.6, 95% CI 1.08-6.5, p = 0.036), lymphovascular invasion (OR 2.47, 95% CI 1.05-6.02, p = 0.041) and SLN ratio (positive SLNs/total SLNs excised) > 0.5 (OR 4.33, 95% CI 1.88-10.4, p < 0.001).
conclusionsThis study proposes factors that predict cALND+ in initially node-positive patients who undergo NAC and have ypN+ disease on SLNB/TAD and identifies patients who should potentially be selected for cALND versus those who maybe be spared.
Indexed as
Identifiers
41296230What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.